B. Metzler Seel. Sohn & Co. Ag Fate Therapeutics Inc Transaction History
B. Metzler Seel. Sohn & Co. Ag
- $9.53 Billion
- Q4 2024
Shares
2 transactions
Others Institutions Holding FATE
# of Institutions
167Shares Held
108MCall Options Held
79.2KPut Options Held
9K-
Redmile Group, LLC San Francisco, CA12.9MShares$18.3 Million1.66% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.3MShares$14.7 Million0.0% of portfolio
-
Black Rock Inc. New York, NY10.1MShares$14.4 Million0.0% of portfolio
-
Bellevue Group Ag Kuesnacht, V84.84MShares$6.87 Million0.16% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il4.38MShares$6.22 Million0.0% of portfolio
About FATE THERAPEUTICS INC
- Ticker FATE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 97,000,304
- Market Cap $138M
- Description
- Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...